Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma

The efficacy of sorafenib in combination with transarterial chemoembolization (TACE) or multiple-line therapies in patients with advanced hepatocellular carcinoma (HCC) remains unclear. This study aimed to investigate the overall survival (OS) of patients with advanced HCC in response to different c...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsiao, Pojen, Hsieh, Kun-Chou, Chen, Yaw-Sen, Hsu, Chia-Chang, Lo, Gin-Ho, Li, Yu-Chan, Hsieh, Pei-Min, Lin, Hung-Yu, Wu, Tsung-Chin, Yeh, Jen-Hao, Lin, Chih-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636964/
https://www.ncbi.nlm.nih.gov/pubmed/31232945
http://dx.doi.org/10.1097/MD.0000000000016074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636964/
https://www.ncbi.nlm.nih.gov/pubmed/31232945
http://dx.doi.org/10.1097/MD.0000000000016074

Ejemplares similares